Mnemonic for Oral Antidiabetic Drug Classes
Use "MIST-SG" to memorize the major oral antidiabetic drug classes: Metformin, Insulin secretagogues (Sulfonylureas), Thiazolidinediones, SGLT-2 inhibitors, DPP-4 inhibitors, and α-Glucosidase inhibitors.
Breaking Down the Mnemonic
The mnemonic "MIST-SG" captures all FDA-approved oral antidiabetic classes mentioned in current guidelines 1:
- M = Metformin (Biguanide) - First-line agent
- I = Insulin secretagogues (Sulfonylureas and meglitinides/benzoic acid derivatives)
- S = SGLT-2 inhibitors (Sodium-glucose cotransporter-2 inhibitors)
- T = Thiazolidinediones (TZDs)
- S = Sulfonylureas (can also stand alone as major insulin secretagogue)
- G = Gliptins (DPP-4 inhibitors) and α-Glucosidase inhibitors
Alternative Classification Framework
You can also organize these by mechanism using "SUGAR MIST":
- S = Secretagogues (Sulfonylureas, Meglitinides)
- U = Uptake blockers (α-Glucosidase inhibitors - block carbohydrate absorption)
- G = Gliptins (DPP-4 inhibitors)
- A = Action enhancers (Thiazolidinediones - enhance insulin action)
- R = Renal glucose dumpers (SGLT-2 inhibitors)
- M = Metformin (reduces hepatic glucose production)
Clinical Context from Guidelines
The ACP guidelines 1 emphasize that metformin is the clear first-line agent, with second-line options including sulfonylureas, thiazolidinediones, SGLT-2 inhibitors, or DPP-4 inhibitors. This hierarchy matters more than memorization alone.
The evidence distinguishes between hypoglycemic agents (sulfonylureas and benzoic acid derivatives that can cause hypoglycemia) versus antihyperglycemic agents (metformin, α-glucosidase inhibitors, and thiazolidinediones that do not cause hypoglycemia when used alone) 2, 3.
Practical Application
Mnemonics work by linking information to well-known patterns and can improve clinical decision-making 4, 5. However, knowing the classes is only the starting point—understanding their mechanisms, adverse effects, and appropriate patient selection based on weight, renal function, cardiovascular risk, and hypoglycemia risk is essential for safe prescribing 1, 3.